News
RGEN
138.82
+3.22%
4.33
Analysts Anticipate QQQJ Will Reach $34
NASDAQ · 13h ago
Wolfe’s tax loss selling stocks within communications, discretionary, staples, energy, financials, health care
Seeking Alpha · 1d ago
TimesSquare U.S. Mid Cap Growth Strategy Q3 2024 Commentary
Seeking Alpha · 1d ago
Morgan Stanley’s list of tax loss selling stocks
Seeking Alpha · 4d ago
Weekly Report: what happened at RGEN last week (0930-1004)?
Weekly Report · 4d ago
Morgan Stanley identifies 39 stocks likely to face tax loss selling pressure
Seeking Alpha · 10/02 14:54
Weekly Report: what happened at RGEN last week (0923-0927)?
Weekly Report · 09/30 09:10
Voya Small Cap Growth Fund Quarterly Q2 2024 Commentary
Seeking Alpha · 09/27 15:50
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
TipRanks · 09/27 12:40
Voya SmallCap Opportunities Portfolio Q2 2024 Commentary
Seeking Alpha · 09/27 09:35
Voya Large Cap Growth Strategy Q2 2024 Commentary
Seeking Alpha · 09/26 16:15
Evaluating Repligen: Insights From 6 Financial Analysts
Benzinga · 09/26 15:00
Repligen Price Target Maintained With a $205.00/Share by RBC Capital
Dow Jones · 09/26 14:28
RBC Capital Reiterates Outperform on Repligen, Maintains $205 Price Target
Benzinga · 09/26 14:19
Repligen Insiders Sell US$12m Of Stock, Possibly Signalling Caution
Simply Wall St · 09/26 11:02
Repligen (RGEN) Receives a Buy from RBC Capital
TipRanks · 09/26 01:48
Repligen Opens Training & Innovation Center to Elevate Customer Experience
Barchart · 09/24 06:30
Weekly Report: what happened at RGEN last week (0916-0920)?
Weekly Report · 09/23 09:10
Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)
TipRanks · 09/19 13:06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA) and Repligen (RGEN)
TipRanks · 09/19 10:41
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.